Senolytic therapies for healthy longevity.
Open accessAbstract
Clearing senescent cells with targeted drugs could combat age-associated disease
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
D + Q and the BCL-2 inhibitors ABT-263 and ABT-737 are the most frequently used senolytics in vivo, showing promise in improving a wide range of pathologies.
“D + Q and the BCL-2 inhibitors, ABT-263 (Navitoclax) and ABT-737, are the most frequently used senolytics in vivo, showing promise in improving a wide range of pathologies (van Deursen 2019).”
From Senescence and the SASP: many therapeutic avenues (2020) · cites this paper as van Deursen 2019
In “Clearing senescent cells with targeted drugs to combat age-related disease” (page unavailable), the paper identifies ABT-263 and ABT-737 as senolytics, mentions dasatinib with quercetin, and reports that ABT-263 attenuated disease phenotypes in mouse models of atherosclerosis and neurodegeneration. It does not say these are the most frequently used senolytics in vivo or establish improvements across a wide range of pathologies for all three treatments. (LLM, conf=0.86)
Experimental — accuracy not yet measuredABT-263 and ABT-737 are the most frequently used senolytics in vivo and show promise in improving a wide range of pathologies.
“ABT-737, are the most frequently used senolytics in vivo, showing promise in improving a wide range of pathologies (van Deursen 2019).”
From Senescence and the SASP: many therapeutic avenues (2020) · cites this paper as van Deursen 2019
In “Clearing senescent cells with targeted drugs to combat age-related disease” (page not available), the paper identifies ABT-263 and ABT-737 as senolytics and reports that ABT-263 attenuated disease phenotypes in mouse models of atherosclerosis and neurodegeneration. It does not say these are the most frequently used senolytics in vivo or establish improvements across a wide range of pathologies for both drugs. (LLM, conf=0.86)
Experimental — accuracy not yet measuredAccumulating evidence has demonstrated that both anti-senescence and pro-senescence therapies could be beneficial depending on the context.
“Accumulating evidence has demonstrated that both anti-senescence and pro-senescence therapies could be beneficial depending on the context (Myrianthopoulos et al., 2019; van Deursen, 2019).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as van Deursen, 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 16 · Cited by 237
Research works printed but not linked: 2
- [11]Munoz-Espin D, EMBO Mol Med 10, (2018). PMC6127887 30012580
- [14]Munoz-Espin D, Cell 155, 1104– 1118 (2013). 24238962
- Authors
- van Deursen, J. M.
- Affiliations
- Departments of Biochemistry and Molecular Biology, and Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN 55905, USA.
- Venue
- Science
- Published
- 2019-05-17
- Volume
- 364
- Issue
- 6441
- Pages
- 636-637
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC6816502
- OpenAlex
- W2946521685
- Cited by
- 237
- References
- 16
- Citations by year
- 2026: 16 · 2025: 19 · 2024: 42 · 2023: 37 · 2022: 42 · 2021: 36 · 2020: 36 · 2019: 9
- FWCI
- 21.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (R01AG057493)
- National Cancer Institute (R01CA096985)
- Topics
- Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Keywords
- senolytics, senescent cells, cellular senescence, healthy aging, age-related diseases
- MeSH terms
- Healthy Aging, Animals, Humans, Longevity, Neoplasms, Rejuvenation, Cellular Senescence, Apoptosis, Neurodegenerative Diseases, Models, Animal, Atherosclerosis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
